[ERCC1作为卵巢癌对铂类药物耐药的标志物]。

Q4 Medicine Antibiotiki i Khimioterapiya Pub Date : 2015-01-01
T A Bogush, A S Popova, E A Dudko, E A Bogush, A S Tyulyandina, S A Tyulyandin, M I Davydov
{"title":"[ERCC1作为卵巢癌对铂类药物耐药的标志物]。","authors":"T A Bogush,&nbsp;A S Popova,&nbsp;E A Dudko,&nbsp;E A Bogush,&nbsp;A S Tyulyandina,&nbsp;S A Tyulyandin,&nbsp;M I Davydov","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer. All the variants of the laboratory and clinical ERCC1 assessment in the ovarian cancer tissue (single nucleotide polymorphisms of the ERCC1 gene, levels of mRNA or protein) are considered. Data on the prognostic and predictive value of ERCC1 as a marker of the response to platinum-based therapy in ovarian cancer are systematized. The authors discuss the possible causes of heterogeneity of the results and emphasize the necessity of a unified and integrated approach to evaluation of ERCC1 in the tumor. The publications cited in the Search Engine Pub Med up to January 2015 were analyzed.</p>","PeriodicalId":53646,"journal":{"name":"Antibiotiki i Khimioterapiya","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].\",\"authors\":\"T A Bogush,&nbsp;A S Popova,&nbsp;E A Dudko,&nbsp;E A Bogush,&nbsp;A S Tyulyandina,&nbsp;S A Tyulyandin,&nbsp;M I Davydov\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer. All the variants of the laboratory and clinical ERCC1 assessment in the ovarian cancer tissue (single nucleotide polymorphisms of the ERCC1 gene, levels of mRNA or protein) are considered. Data on the prognostic and predictive value of ERCC1 as a marker of the response to platinum-based therapy in ovarian cancer are systematized. The authors discuss the possible causes of heterogeneity of the results and emphasize the necessity of a unified and integrated approach to evaluation of ERCC1 in the tumor. The publications cited in the Search Engine Pub Med up to January 2015 were analyzed.</p>\",\"PeriodicalId\":53646,\"journal\":{\"name\":\"Antibiotiki i Khimioterapiya\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibiotiki i Khimioterapiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotiki i Khimioterapiya","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

本文综述了核苷酸切除修复的关键标志物ERCC1及其在卵巢癌铂耐药中的作用。考虑了卵巢癌组织中实验室和临床ERCC1评估的所有变异(ERCC1基因的单核苷酸多态性,mRNA或蛋白质水平)。关于ERCC1作为卵巢癌铂基治疗反应标志物的预后和预测价值的数据被系统化。作者讨论了结果异质性的可能原因,并强调有必要采用统一和综合的方法来评估肿瘤中的ERCC1。分析了截至2015年1月在Search Engine Pub Med中被引用的出版物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].

The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer. All the variants of the laboratory and clinical ERCC1 assessment in the ovarian cancer tissue (single nucleotide polymorphisms of the ERCC1 gene, levels of mRNA or protein) are considered. Data on the prognostic and predictive value of ERCC1 as a marker of the response to platinum-based therapy in ovarian cancer are systematized. The authors discuss the possible causes of heterogeneity of the results and emphasize the necessity of a unified and integrated approach to evaluation of ERCC1 in the tumor. The publications cited in the Search Engine Pub Med up to January 2015 were analyzed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Antibiotiki i Khimioterapiya
Antibiotiki i Khimioterapiya Medicine-Infectious Diseases
CiteScore
0.80
自引率
0.00%
发文量
46
期刊最新文献
Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts Dynamics of Reserve Antimicrobial Drug Consumption in Russian Hospitals: Impact of the COVID-19 Pandemic Rationality of Cytoflavin Inclusion in the Treatment of Patients with Dermatological Pathology Comorbid with Mental Disorders Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment The Results of Preclinical Studies Assessing the Effect of Riamilovir on the Reproductive Function and Postnatal Growth of Offspring in Laboratory Animals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1